Head-to-head evidence
Gefitinib vs HLX07
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
Gefitinib
Marketed by AstraZeneca
NCT00020709 · Phase 3 · completed
This was a large, randomized, double-blind, placebo-controlled trial with 840 participants and hard clinical primary endpoints of overall survival and progression-free survival. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: October 2026 · NCT03333343 (registry estimate)
HLX07
Developed by Shanghai Henlius Biotech
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2030 · NCT07459751 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gefitinib's landscape · HLX07's landscape